Market Research Report
Th17 Inflammatory Pathway Therapeutics
|Published by||Greystone Research Associates||Product code||892533|
Delivery time: 1-2 business days
|Th17 Inflammatory Pathway Therapeutics|
|Published: July 22, 2019||Content info:||
Immune-mediated inflammatory diseases (IMIDs) is a term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well. Examples include type 1 diabetes (T1D), Crohn's disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis. This report examines the therapeutic products and strategies that are being employed to improve outcomes by modulating the intracellular production of inflammatory mediators.